e-Drug3D

1484

cas 504-24-5

CLASS

NERVOUS SYSTEM
MULTIPLE SCLEROSIS
BROAD SPECTRUM POTASSIUM ION CHANNELS INHIBITOR (KV)
INDICATED TO IMPROVE WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

ROUTE (list)

ORAL

PK parameters

F 96 PERCENT
VD 169 LITER (65 KILOGRAM)
Cl 20 LITER / HOUR (EQN)
PPB 98 PERCENT
t1/2 5.8 HOUR

MW 94.12
NB_atoms 7
XLogP 0.66
PSA 35.21
NB_HD 2
NB_HA 2
fsp3 0.00
Lipinski(0=no;1=yes) 1

FDA
NDA 022250 (label) INN (DALFAMPRIDINE) AMPYRA (MERZ) APPROVAL= AP YEAR= 2010 NEWMOLECULARENTITY
NDA 206854 (pdf not found) INN (DALFAMPRIDINE) DALFAMPRIDINE (TEVA PHARMS USA INC) APPROVAL= TA YEAR= 2016
NDA 206811 (pdf not found) INN (DALFAMPRIDINE) DALFAMPRIDINE (AUROBINDO PHARMA) APPROVAL= AP YEAR= 2017
NDA 206836 (pdf not found) INN (DALFAMPRIDINE) DALFAMPRIDINE (ACTAVIS LABS FL INC) APPROVAL= AP YEAR= 2017
NDA 206646 (pdf not found) INN (DALFAMPRIDINE) DALFAMPRIDINE (HIKMA) APPROVAL= AP YEAR= 2018 DISCONTINUED
NDA 206765 (pdf not found) INN (DALFAMPRIDINE) DALFAMPRIDINE (ALKEM LABS LTD) APPROVAL= AP YEAR= 2018
NDA 206863 (pdf not found) INN (DALFAMPRIDINE) DALFAMPRIDINE (ACCORD HLTHCARE) APPROVAL= AP YEAR= 2018
NDA 208292 (pdf not found) INN (DALFAMPRIDINE) DALFAMPRIDINE (SUN PHARM) APPROVAL= AP YEAR= 2019 DISCONTINUED
NDA 210158 (pdf not found) INN (DALFAMPRIDINE) DALFAMPRIDINE (MICRO LABS) APPROVAL= AP YEAR= 2019
NDA 206858 (pdf not found) INN (DALFAMPRIDINE) DALFAMPRIDINE (RISING) APPROVAL= AP YEAR= 2020 DISCONTINUED